Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01670773 · ClinicalTrials.gov registry record · Phase 1
A Study of CAT-1004 Biomarkers in Healthy Subjects
A Phase 1 study of Assessment of Mechanistic Blood Biomarkers in Healthy Humans, sponsored by Catabasis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT01670773 is a Phase 1 study of Assessment of Mechanistic Blood Biomarkers in Healthy Humans that has completed, run by Catabasis Pharmaceuticals. The registered enrollment target is 9 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01670773, a Phase 1 study of Assessment of Mechanistic Blood Biomarkers in Healthy Humans, has completed, sponsored by Catabasis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being conducted to assess mechanistic blood biomarkers of CAT-1004 in healthy humans.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CAT-1004
- DRUG Salsalate + DHA
Study Locations (1)
Massachusetts
- ProMedica - Brighton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-08 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01670773
The ClinicalTrials.gov registry entry for NCT01670773 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Catabasis Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Assessment of Mechanistic Blood Biomarkers in Healthy Humans appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01670773 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01670773 about?
NCT01670773 is a clinical study titled "A Study of CAT-1004 Biomarkers in Healthy Subjects". This study is being conducted to assess mechanistic blood biomarkers of CAT-1004 in healthy humans.
What is the current status of trial NCT01670773?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2012-08. Estimated completion is 2012-10.
What conditions does trial NCT01670773 study?
This clinical trial studies the following conditions: Assessment of Mechanistic Blood Biomarkers in Healthy Humans.
What interventions are being tested in trial NCT01670773?
The interventions under investigation include: Placebo (DRUG), CAT-1004 (DRUG), Salsalate + DHA (DRUG).
Who is sponsoring clinical trial NCT01670773?
This trial is sponsored by Catabasis Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01670773 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.